Eyenovia, Inc. Announces Underwriters’ Full Exercise of Over-Allotment Option in Public Offering
July 16 2019 - 4:05PM
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose
therapeutics utilizing its patented piezo-print technology, today
announced that the underwriters of its previously announced public
offering of common stock have fully exercised their option to
purchase an additional 658,273 shares at the public offering price
of $2.78 per share.
After giving effect to the full exercise of the
over-allotment option, the total number of shares sold by Eyenovia
in the public offering increased to 5,046,763 shares and net
proceeds to Eyenovia from the public offering, after deducting
underwriting discounts and commissions and offering expenses
payable by Eyenovia, increased to approximately $13.0 million.
Eyenovia intends to use the net proceeds from the public offering,
together with other available funds, for the MicroProst and
MicroPine clinical studies and for working capital and general
corporate purposes. The exercise of the over-allotment option is
expected to close on July 18, 2019, subject to customary closing
conditions.
Oppenheimer & Co. Inc. acted as the sole
book-running manager for the offering. Ladenburg Thalmann & Co.
Inc. acted as the lead manager for the offering. National
Securities Corporation acted as the co-manager for the
offering.
The offering was made pursuant to a shelf
registration statement on Form S-3 (File No. 333-229365) that was
declared effective by the Securities and Exchange Commission (the
“SEC”) on February 12, 2019. A final prospectus supplement related
to the offering has been filed with the SEC and is available on the
SEC’s website, located at www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus relating to
the offering may also be obtained from Oppenheimer & Co. Inc.,
Attention: Syndicate Prospectus Department, 85 Broad Street, 26th
Floor, New York, NY, 10004, by telephone at (212) 667-8055, or by
email at EquityProspectus@opco.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities nor
shall there be any offer or sale of these securities in any state
or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic
biopharmaceutical company developing a pipeline of microdose
therapeutics utilizing its patented piezo-print technology.
Eyenovia’s pipeline is currently focused on the late-stage
development of microdosed medications for mydriasis, myopia
progression, glaucoma and other eye diseases.
Forward-Looking
StatementsExcept for historical information, all of the
statements, expectations, and assumptions contained in this press
release are forward-looking statements. Forward-looking statements
include, but are not limited to, statements that express our
intentions, beliefs, expectations, strategies, predictions or any
other statements relating to our future activities or other future
events or conditions. These statements are based on current
expectations, estimates and projections about our business based,
in part, on assumptions made by management. These statements are
not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may, and are likely to,
differ materially from what is expressed or forecasted in the
forward-looking statements due to numerous factors discussed from
time to time in documents which we file with the SEC. In addition,
such statements could be affected by risks and uncertainties
related to, among other things, the Company’s expectations
regarding its anticipated use of the net proceeds from the public
offering and its need to raise additional capital even after this
financing. Any forward-looking statements speak only as of the date
on which they are made, and except as may be required under
applicable securities laws, Eyenovia does not undertake any
obligation to update any forward-looking statements.
Company Contact:Eyenovia, Inc.
John GandolfoChief Financial Officerjgandolfo@eyenoviabio.com
Investor Contact:The Ruth
GroupTram Bui / Alexander LoboPhone:
646-536-7035/7037tbui@theruthgroup.com / alobo@theruthgroup.com
Media Contact:The Ruth
GroupKirsten Thomas508-280-6592kthomas@theruthgroup.com
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Sep 2023 to Sep 2024